Checkpoint Inhibitors for Treatment of NMIBC

Experts share their initial impressions of the available data on immunotherapies, including PD-L1 inhibitors durvalumab and sasanlimab, being evaluated in bacille Calmette-Guérin (BCG)–unresponsive patients with non–muscle-invasive bladder cancer (NMIBC).

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

EP: 2.Cystectomy in NMIBC

EP: 3.New Intravesical Delivery Systems and TAR-200 in NMIBC

EP: 4.TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP: 5.TAR-200 Clinical Development Program in NMIBC

EP: 6.Other Investigational Drug Delivery Systems in NMIBC

EP: 7.Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP: 8.FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP: 9.Use and Sequencing of Novel Treatments in NMIBC

EP: 10.Communication of Treatment Options for High-Risk NMIBC

Now Viewing

EP: 11.Checkpoint Inhibitors for Treatment of NMIBC

Video content above is prompted by the following:

• In addition to recent approval, several immunotherapies such as PD-(L)-1 inhibitors (durvalumab and sasanlimab) are being evaluated in BCG-unresponsive patients. What are your initial impressions of available data with immunotherapies?

Related Videos

Communication of Treatment Options for High-Risk NMIBC

Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment

Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment

BPH: The Patient Journey

Addressing Remaining Unmet Needs in mCRPC

Use and Sequencing of Novel Treatments in NMIBC

The DORA Trial

FDA-Approved Treatments for BCG-Unresponsive NMIBC

Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

Clinical Perspectives on Early Use of RAD-ENZ